サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513935

腎臓がん治療薬の世界市場

Kidney Cancer Drugs

出版日
ページ情報
英文 148 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
腎臓がん治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 148 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

腎臓がん治療薬の世界市場は2030年までに81億米ドルに達する見込み

2023年に58億米ドルと推定された腎臓がん治療薬の世界市場は、分析期間2023-2030年にCAGR 4.8%で成長し、2030年には81億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 5.2%を記録し、分析期間終了時には56億米ドルに達すると予測されます。免疫療法分野の成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 8.2％で成長予測

米国の腎臓がん治療薬市場は2023年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と4.0％と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界の腎臓がん治療薬市場- 主要動向と促進要因のまとめ

腎臓がんは、治療に対するさまざまな挙動や反応を特徴とする複雑な疾患であるため、腫瘍の特異的な特徴に基づく微妙なアプローチが必要です。初期の治療戦略は、早期段階での外科的介入から、後期段階での高度な薬理学的治療まで多岐にわたり、がん細胞の増殖と拡散を制御するように設計された生物学的療法や標的療法が含まれます。生物学的療法は特定の分子を標的とすることで腫瘍の増殖を阻害し、標的療法はがん細胞の増殖と生存に重要な分子標的に焦点を当てる。これらの先進的な治療法は、腎臓がんの治療状況を大きく変え、多くの患者に新たな希望と長期にわたるコントロールの可能性を提供しています。現在進行中の調査は、これらの治療を最適化し、その有効性を高め、包括的な治療レジームに統合することを目的としています。

進行腎がんの治療は、がん進行の重要な局面を標的とするチロシンキナーゼ阻害剤（TKI）と免疫療法によって革命的に変化しました。スニチニブやパゾパニブなどのTKIは、がん細胞の増殖と腫瘍への血液供給に不可欠な酵素を阻害し、腫瘍の飢餓状態を効果的に作り、腫瘍の進展を抑制します。ニボルマブのような免疫療法は、がん細胞が免疫システムを回避する能力を破壊し、がん細胞に対する身体の自然免疫反応を強化します。ニボルマブのような薬剤とイピリムマブやTKIなどの他の薬剤を組み合わせる併用療法の開発は、治療効果をさらに高め、進行腎臓がん患者の予後を改善することが証明されつつあります。このような治療戦略では、患者とヘルスケアプロバイダーが十分に話し合い、ベネフィットとリスクを慎重に検討し、新たな治療法へのアクセスを提供する新たな臨床試験を検討する必要があります。

腎臓がん治療薬市場は、その成長と進化に寄与する複数の要因によって牽引されています。分子生物学とがんゲノム科学によって拍車がかかった医薬品開発の技術的進歩は、副作用の少ない、より的を絞った効果的な治療を可能にし、患者や腫瘍の特定の遺伝子プロファイルに合わせた精密医療へのシフトを促進します。画期的治療薬の早期承認や希少疾病用医薬品の優遇措置など、規制当局の支援も革新的治療の迅速なイントロダクションを後押ししています。医薬品開発における人工知能の統合は、新薬の発見と試験を合理化し、時間とコストを削減します。製薬会社、バイオテクノロジー企業、学術機関の連携は、開発パイプラインを強化します。さらに、利便性が高く通院回数を減らせる外来がん治療への嗜好が高まっています。患者の支持と意識の向上が早期診断と早期治療につながり、経済成長と保険適用の向上が、高額になりがちな新しい治療法の採用を後押ししています。肥満や高血圧の増加など世界の健康動向は、効果的な腎臓がん治療への需要をさらに高め、継続的な革新と成長を目指すダイナミックな市場を形成しています。

調査対象企業の例（全12件）

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6797

Global Kidney Cancer Drugs Market to Reach US$8.1 Billion by 2030

The global market for Kidney Cancer Drugs estimated at US$5.8 Billion in the year 2023, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$5.6 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.2% CAGR

The Kidney Cancer Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Kidney Cancer Drugs Market - Key Trends and Drivers Summarized

Kidney cancer, a complex disease characterized by variable behavior and response to treatments, requires a nuanced approach based on the specific characteristics of the tumor. Initial treatment strategies range from surgical interventions in early stages to advanced pharmacological treatments in later stages, including biological and targeted therapies designed to control the growth and spread of cancer cells. Biological therapies interfere with tumor growth by targeting specific molecules, while targeted therapies focus on molecular targets that are crucial for cancer cell proliferation and survival. These advanced therapies have significantly transformed the treatment landscape for kidney cancer, offering new hope and prolonged control over the disease for many patients. Ongoing research aims to optimize these treatments, enhancing their effectiveness and integrating them into comprehensive treatment regimes.

The treatment of advanced kidney cancer has been revolutionized by Tyrosine Kinase Inhibitors (TKIs) and immunotherapies that target critical aspects of cancer progression. TKIs, such as sunitinib and pazopanib, block enzymes essential for cancer cell growth and tumor blood supply, effectively starving and inhibiting tumor development. Immunotherapies like nivolumab disrupt cancer cells' ability to evade the immune system, enhancing the body’s natural immune response against cancer cells. The development of combination therapies, which pair drugs like nivolumab with other agents such as ipilimumab or TKIs, is proving to further enhance treatment efficacy, offering improved outcomes for patients with advanced kidney cancer. These treatment strategies necessitate thorough discussions between patients and healthcare providers to carefully weigh the benefits and risks, along with considerations for new clinical trials that offer access to emerging therapies.

The market for kidney cancer drugs is driven by multiple factors that contribute to its growth and evolution. Technological advances in drug development, spurred by molecular biology and cancer genomics, allow for more targeted and effective therapies with fewer side effects, fostering a shift towards precision medicine tailored to specific genetic profiles of patients and tumors. Regulatory support, including accelerated approvals for breakthrough therapies and incentives for orphan drugs, aids in the rapid introduction of innovative treatments. The integration of artificial intelligence in drug development streamlines the discovery and testing of new drugs, reducing time and cost. Collaborations among pharmaceutical companies, biotechnology firms, and academic institutions enhance the development pipeline. Moreover, there is an increasing preference for outpatient cancer therapies that offer convenience and reduce hospital visits. Patient advocacy and enhanced awareness lead to earlier diagnosis and treatment, while economic growth and better insurance coverage support the adoption of new, often costly, treatments. Global health trends, including rising obesity and hypertension rates, further drive the demand for effective kidney cancer treatments, shaping a dynamic market poised for continued innovation and growth.

Select Competitors (Total 12 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Kidney Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Kidney Cancer Propels Demand for Effective Treatment Options
    • Increasing Awareness and Early Diagnosis of Kidney Cancer Accelerates Market Penetration
    • Advances in Targeted Therapy and Immunotherapy Strengthen Business Case for Innovative Kidney Cancer Drugs
    • Focus on Personalized Medicine Drives Adoption of Precision Kidney Cancer Drugs
    • Growing Geriatric Population and Associated Cancer Risk Spurt Growth in Kidney Cancer Drugs Market
    • Introduction of Combination Therapies Throws the Spotlight on Enhanced Treatment Efficacy
    • Advances in Biomarker Identification Propel Development of Targeted Kidney Cancer Drugs
    • Focus on Minimizing Side Effects and Improving Quality of Life Sustains Demand for Innovative Drugs
    • Growing Adoption of Oral Chemotherapy Drugs Expands Treatment Options for Patients
    • Advances in Molecular Diagnostics Propel Growth in Precision Medicine for Kidney Cancer
    • Increasing Number of Clinical Trials and Pipeline Drugs Enhance Market Potential
    • Expansion of Telemedicine and Remote Patient Monitoring Drives Market Adoption
    • Focus on Patient-Centric Care Models Generates Demand for Personalized Kidney Cancer Treatments
    • Advances in Drug Delivery Systems Propel Development of Novel Kidney Cancer Therapies
    • Rising Prevalence of Lifestyle-Related Risk Factors Expands Addressable Market Opportunity
    • Development of Biosimilars and Generics Throws the Spotlight on Affordable Treatment Options
    • Increasing Focus on Integrative and Complementary Therapies Drives Demand for Holistic Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Angiogenesis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Angiogenesis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for mTOR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for mTOR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cytokine Immunotherapy (IL-2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cytokine Immunotherapy (IL-2) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Kidney Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • JAPAN
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • CHINA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • EUROPE
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Kidney Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • FRANCE
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • GERMANY
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Kidney Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • INDIA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Kidney Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Kidney Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Kidney Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030
  • AFRICA
    • Kidney Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Kidney Cancer Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Targeted Therapy and Immunotherapy for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Kidney Cancer Drugs by Pharmacologic Class - Percentage Breakdown of Value Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) for the Years 2014, 2024 & 2030

IV. COMPETITION